Scpharmaceuticals Inc Expected to Earn FY2022 Earnings of $2.70 Per Share (SCPH)

Scpharmaceuticals Inc (NASDAQ:SCPH) – Equities research analysts at Leerink Swann raised their FY2022 earnings per share estimates for shares of Scpharmaceuticals in a research note issued to investors on Thursday. Leerink Swann analyst A. Fadia now expects that the company will post earnings per share of $2.70 for the year, up from their prior estimate of $2.64. Leerink Swann has a “Outperform” rating and a $20.00 price objective on the stock.

A number of other equities research analysts have also issued reports on the stock. BMO Capital Markets started coverage on shares of Scpharmaceuticals in a report on Tuesday, December 12th. They set an “outperform” rating and a $24.00 target price for the company. Jefferies Group started coverage on shares of Scpharmaceuticals in a report on Tuesday, December 12th. They set a “buy” rating and a $23.00 target price for the company. Finally, Zacks Investment Research lowered shares of Scpharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, February 14th.

Shares of Scpharmaceuticals (NASDAQ:SCPH) opened at $12.42 on Friday. Scpharmaceuticals has a 1-year low of $11.50 and a 1-year high of $18.17.

Scpharmaceuticals (NASDAQ:SCPH) last released its earnings results on Tuesday, March 20th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.53) by ($0.27).

Several hedge funds have recently made changes to their positions in SCPH. Monashee Investment Management LLC acquired a new position in shares of Scpharmaceuticals during the 4th quarter valued at about $230,000. Bank of New York Mellon Corp acquired a new position in Scpharmaceuticals in the fourth quarter valued at about $414,000. Millennium Management LLC acquired a new position in Scpharmaceuticals in the fourth quarter valued at about $462,000. Goldman Sachs Group Inc. acquired a new position in Scpharmaceuticals in the fourth quarter valued at about $653,000. Finally, Bain Capital Public Equity Management LLC acquired a new position in Scpharmaceuticals in the fourth quarter valued at about $1,291,000. 44.22% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: This news story was published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this news story on another site, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.tickerreport.com/banking-finance/3294652/scpharmaceuticals-inc-expected-to-earn-fy2022-earnings-of-2-70-per-share-scph.html.

About Scpharmaceuticals

scPharmaceuticals, Inc, is a biopharmaceutical company. The Company is engaged in developing pharmaceutical products for subcutaneous delivery. The Company offers sc2Wear Infusor, which is a small pump that attaches to the body using a standard medical adhesive. The sc2Wear Infusor injects the drug into the body slowly, similar to an intravenous (IV) drip.

Receive News & Ratings for Scpharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scpharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Zacks: Analysts Anticipate Ares Management  Will Announce Quarterly Sales of $198.50 Million
Zacks: Analysts Anticipate Ares Management Will Announce Quarterly Sales of $198.50 Million
Ascent Capital Group  Expected to Announce Quarterly Sales of $133.40 Million
Ascent Capital Group Expected to Announce Quarterly Sales of $133.40 Million
First Cash Financial Services  Releases Quarterly  Earnings Results, Beats Estimates By $0.15 EPS
First Cash Financial Services Releases Quarterly Earnings Results, Beats Estimates By $0.15 EPS
Mohawk Industries  Announces  Earnings Results
Mohawk Industries Announces Earnings Results
CubeSmart  Releases FY18 Earnings Guidance
CubeSmart Releases FY18 Earnings Guidance
Somewhat Favorable Media Coverage Somewhat Unlikely to Affect American International Group  Stock Price
Somewhat Favorable Media Coverage Somewhat Unlikely to Affect American International Group Stock Price


© 2006-2018 Ticker Report. Google+.